This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio
by Zacks Equity Research
Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.
Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health (CAH) to Open New Distribution Center in Ohio
by Zacks Equity Research
Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
by Zacks Equity Research
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
by Zacks Equity Research
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
by Zacks Equity Research
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
by Zacks Equity Research
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
by Zacks Equity Research
Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.
Omnicell (OMCL) Introduces Central Med Automation Service
by Zacks Equity Research
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
Brookdale (BKD) Down 7% Since Q2 Earnings Miss on Lower Interest
by Zacks Equity Research
Brookdale (BKD) expects adjusted EBITDA for the third quarter in the range of $90-$95 million.
GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare
by Zacks Equity Research
GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.
Boston Scientific (BSX), Silk Road Merger Delayed for Review
by Zacks Equity Research
Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
by Zacks Equity Research
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
by Zacks Equity Research
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches
by Zacks Equity Research
Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.
Microbot Medical (MBOT) Gets Quality Certification for its System
by Zacks Equity Research
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
by Zacks Equity Research
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
by Harshit Gupta
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
by Zacks Equity Research
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.